Drug application
CABAZITAXEL (CABAZITAXEL)
Drugs@FDA ANDA 207619 · BRECKENRIDGE
Key facts
| Drug name | CABAZITAXEL |
|---|---|
| Active ingredients | CABAZITAXEL |
| Application type | ANDA |
| Application number | 207619 |
| Company | BRECKENRIDGE |
| Dosage forms | SOLUTION, INTRAVENOUS |
| Strength | 60MG/1.5ML (40MG/ML) |
| Marketing status | Discontinued |
| TE codes | AP |
| Reference listed drug | No |
| Latest submission status date | Jun 23, 2022 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- 1–9 Therapeutic equivalents
- Yes FDA letters on file
- No FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: